Preparation of novel porous starch microsphere foam for loading and release of poorly water soluble drug

Drug Development and Industrial Pharmacy

Volumn 40, Issue 2, 2014, Pages 252-259

  Jiang, Tongying ^a   Wu, Chao ^b   Gao, Yikun ^a   Zhu, Wenquan ^a   Wan, Long ^a   Wang, Zhanyou ^c   Wang, Siling ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b JINZHOU MEDICAL UNIVERSITY   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Dissolution rate; Lovastatin (LV); Nanometer sized pores; Poorly water soluble drugs; Porous starch microsphere foam (PSM)

Indexed keywords

MEVINOLIN; STARCH MICROSPHERE;

ADSORPTION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CYTOTOXICITY; DESORPTION; DOG; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOPORE; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; SCANNING ELECTRON MICROSCOPY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CACO-2 CELLS; DOGS; FEMALE; HUMANS; MALE; MICROSPHERES; PHARMACEUTICAL PREPARATIONS; POROSITY; SOLUBILITY; STARCH; WATER; X-RAY DIFFRACTION;

EID: 84893210904     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.756511     Document Type: Article

References (46)

1. Badr-Eldin SM, Elkheshen SA, Ghorab MM. Inclusion complexes of tadalafil with natural and chemically modified b-cyclodextrins I: preparation and in-vitro evaluation. Eur J Pharm Biopharm 2008;70:819-27.
2. Karavas E, Georgarakis E, Sigalas MP, et al. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm 2007;66:334-47.
3. Tran PHL, Tran HTT, Lee BJ. Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J Control Release 2008;129:59-65.
4. Yin LF, Huang SJ, Zhu CL, et al. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Drug Dev Ind Pharm 2012;11:1371-80.
5. Zhang ZL, Le Y, Wang JX, et al. Development of stabilized itraconazole nanodispersions by using high-gravity technique. Drug Dev Ind Pharm 2012;12:1512-20.
6. Matteucci ME, Brettmann BK, Rogers TL, et al. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol Pharm 2007;4:782-93.
7. Oh WK, Yoon H, Jang J. Size control of magnetic carbon nanoparticles for drug delivery. Biomaterials 2010;31:1342-8.
8. Chadha R, Gupta S, Pathak N. Artesunate-loaded chitosan/lecithin nanoparticles: Preparation, characterization, and in vivo studies. Drug Dev Ind Pharm 2012;12:1538-46.
9. Masuda K, Tabata S, Kono H, et al. Solid-state13C NMR study of indomethacin polymorphism. Int J Pharm 2006;318:146-53.
10. Zhang YZ, Zhi ZZ, Jiang TY, et al. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control Release 2010;145:257-63.
11. Huang XL, Teng X, Chen D, et al. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 2010;31:438-48.
12. Zhang YZ, Jiang TY, Zhang Q, et al. Inclusion of telmisartan in mesocellular foam nanoparticles: drug loading and release property. Eur J Pharm Biopharm 2010;76:17-23.
13. Kilpelainen, M, Riikonen J, Vlasova MA, et al. In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. J Control Release 2009;137:166-70.
14. Zhang YZ, Zhang JH, Jiang TY, et al. Inclusion of the poorly watersoluble drug simvastatin in mesocellular foam nanoparticles: drug loading and release properties. Int J Pharm 2011;410:118-24.
15. Tan A, Simovic S, Davey AK, et al. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J Control Release 2009;134:62-70.
16. Foldvari M, Bagonluri M. Carbon nanotubes as functional excipients for nanomedicines:II. Drug delivery and biocompatibility issues. Nanomedicine: NBM. 2008;4:183-200.
17. Cheng JP, Mezianib MJ, Sun YP, et al. Poly(ethylene glycol)- conjugated multi-walled carbon nanotubes as an efficient drug carrier for overcoming multidrug resistance. Toxicol Appl Pharm 2011;250:184-93.
18. Kapoor S, Hegde R, Bhattacharyya AJ. Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release. J Control Release 2009;140:34-9.
19. Yang PP, Quan ZW, Lib CX, et al. Bioactive, luminescent and mesoporous europium-doped hydroxyapatite as a drug carrier. Biomaterials 2008;29:4341-7.
20. Ye F, Guo HF, Zhang HJ, et al. Polymeric micelle-templated synthesis of hydroxyapatite hollow nanoparticles for a drug delivery system. Acta Biomaterialia 2010;6:2212-18.
21. Zhou TH, Su M, Shang BC, et al. Nano-hydroxyapatite/b-tricalcium phosphate ceramics scaffolds loaded with cationic liposomal ceftazidime: preparation, release characteristics in vitro and inhibition to Staphylococcus aureus biofilms. Drug Dev Ind Pharm 2012;11:1298-304.
22. Duartea ARC, Mano JF, Reis RL. Preparation of starch-based scaffolds for tissue engineering by supercritical immersion precipitation. J Supercrit Fluid 2009;49:279-85.
23. Boesel LF, Mano JF, Reis RL. Optimization of the formulation and mechanical properties of starch based partially degradable bone cements. J Mater Sci-Mater M 2004;15:1-8.
24. Jain AK, Khar RK, Ahmed FJ, et al. Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm 2008;69:426-35.
25. Santander-Ortega MJ, Stauner T, Loretz B, et al. Nanoparticles made from novel starch derivatives for transdermal drug delivery. J Control Release 2010;141:85-92.
26. El-Hag Ali A, AlArifi A. Characterization and in vitro evaluation of starch based hydrogels as carriers for colon specific drug delivery systems. Carbohyd Polym 2009;78:725-30.
27. Elviraa C, Manoa JF, San Roman J, et al. Starch-based biodegradable hydrogels with potential biomedical applications as drug delivery systems. Biomaterials 2002;23:1955-66.
28. Marques AP, Reis RL, Hunt JA. The biocompatibility of novel starch-based polymers and composites: in vitro studies. Biomaterials 2002;23:1471-8.
29. Araujo MA, Cunha AM, Mota M. Enzymatic degradation of starch-based thermoplastic compounds used in protheses: identification of the degradation products in solution. Biomaterials 2004;25:2687-93.
30. Lee SY, Eskridge KM, Koh WY, et al. Evaluation of ingredient effects on extruded starch-based foams using a supersaturated split-plot design. Ind Crop Prod 2009;29:427-36.
31. Malafaya PB, Elvira C, Gallardo A, et al. Porous starch-based drug delivery systems processed by a microwave route. J Biomater Sci Polymer Edn 2001;12:1227-41.
32. Glenn GM, Imam SH, Klamczynski AP, et al. Structure of porous starch microcellular foam particles. Microsc Microanal 2008;14:150-1.
33. Wanga HQ, Wanga QF, Daia QY, et al. Preparation of novel porous carbon spheres from corn starch. Colloid Surface A 2009;346:213-15.
34. Wu C, Wang ZY, Zhi ZZ, et al. Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs. Int J Pharm 2011;403:162-9.
35. Takeuchi H, Nagira S, Yamamoto H, et al. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm 2005;293:155-64.
36. Mehramizi A, Asgari Monfared E, Pourfarzib M, et al. Influence of b - cyclodextrin complexation on lovastatin release from osmotic pump tablets (OPT). Daru 2007;15:71-8.
37. Suresh G, Manjunath K, Venkateswarlu V, et al. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007;8:E162-7.
38. Kapitza SB, Michel BR, Hoogevest PV, et al. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model. Eur J Pharm Biopharm 2007;66:146-58.
39. Rouquerol J, Avnir D, Fairbridge CW, et al. Recommendations for the characterization of porous solids. Pure Appl Chem 1994;66:1739.
40. Kapoor S, Hegde R, Bhattacharyya AJ. Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release. J Control Release 2009;140:34-9.
41. Zhang YM, Hu LY, Han JC, et al. Soluble starch scaffolds with uniaxial aligned channel structure for in situ synthesis of hierarchically porous silica ceramics. Micropor Mesopor Mat 2010;130:327-32.
42. Yiotis AG, Stubos AK, Boudouvis AG, et al. A 2-D pore-network model of the drying of single-component liquids in porous media. Adv Water Resour 2001;24:439-60.
43. Jiang TY, Han N, Zhao BW, et al. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. Drug Dev Ind Pharm 2012;10:1230-9.
44. Tai'zia DS, Valqui'ria TA, Jackson ALCR, et al. Preparation and characterization of solid dispersion of simvastatin. Drug Dev Ind Pharm 2010;11:1348-55.
45. Sharma P, Chawla HPS, Panchagnula R. Analytical method for monitoring concentrations of cyclosporin and lovastatin in vitro in an everted rat intestinal sac absorption model. J Chromatogr B 2002;768:349-59.
46. Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev 1991;7:71-86.